New weight loss pill that’s beating oral Ozempic
AI Generated Image

New weight loss pill that’s beating oral Ozempic

NewsNation health

Key Points:

  • A Phase 3 clinical trial involving 1,698 adults with Type 2 diabetes found that the new daily weight-loss pill orforglipron outperformed oral semaglutide (Ozempic) in lowering blood sugar and promoting weight loss.
  • Orforglipron reduced HbA1c levels by 1.71% to 1.91%, compared to a 1.47% reduction with oral semaglutide, while participants lost an average of 15 pounds versus 10 pounds with semaglutide.
  • Marketed as Foundayo and manufactured by Eli Lilly, orforglipron received FDA approval in April and is currently being studied for use in people with obesity without diabetes.

Trending Business

Trending Technology

Trending Health